To minimize systemic immune toxicities, we have developed a novel 4-1BB x 5T4 bispecific antibody designed to direct tumor- specific T cell responses to the tumor microenvironment by stimulating 4-1BB function only when co-engaged with 5T4, a tumor-associated antigen. Here, TNFRSF9 is linked to neoplasm.